Resveratrol inhibits nonalcoholic fatty liver disease in rats
Open Access
- 9 September 2008
- journal article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 8 (1) , 40
- https://doi.org/10.1186/1471-230x-8-40
Abstract
The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic steatosis in an animal model of steatosis, and whether this therapeutic approach resulted in a decrease in tumor necrosis factor α (TNF-α) production, lipid peroxidation and oxidative stress.Keywords
This publication has 38 references indexed in Scilit:
- Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitisGut, 2007
- Nonalcoholic Fatty Liver Disease in Severely Obese SubjectsAmerican Journal of Gastroenterology, 2007
- Effect of resveratrol on alcohol-induced mortality and liver lesions in miceBMC Gastroenterology, 2006
- The Prevalence of Nonalcoholic Steatohepatitis is Greater in Morbidly Obese Men Compared to WomenObesity Surgery, 2006
- Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implicationsMolecular Nutrition & Food Research, 2005
- Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological LesionsAmerican Journal of Gastroenterology, 1999
- A new model of acute liver steatosis induced in rats by fasting followed by refeeding a high carbohydrate-fat free diet. Biochemical and morphological analysis.Journal of Hepatology, 1997
- Nonalcoholic SteatohepatitisAnnals of Internal Medicine, 1997
- Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from GrapesScience, 1997
- Assay for lipid peroxides in animal tissues by thiobarbituric acid reactionAnalytical Biochemistry, 1979